Pfizer Triggers $28 Billion Stock Plunge After Warning Covid Vaccine Sales May Disappoint This Year
ForbesJUL 2022
Riding the windfall of its COVID vaccines, Pfizer is busy scouring the biopharma landscape and gobbling up a plethora of smaller companies. It should be telling that in the event of "antitrust-related circumstances," Pfizer would owe Global Blood Therapeutics a whopping $326M.
Pfizer's new biotech buyouts will have a net positive impact on the most important stakeholders - consumers. This allows for better dissemination of existing treatments through Pfizer's formidable distribution networks and helps to build a bold research pipeline. Patients are the true winners.